Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome
Singhal S, Riggs E, Ruth K, Chavez-Salas J, Chertock Y, Daly M, Hall M. Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome. JCO Precision Oncology 2024, 8: e2400562. PMID: 39546469, PMCID: PMC11573245, DOI: 10.1200/po-24-00562.Peer-Reviewed Original ResearchConceptsLynch syndromeLifetime risk of colorectal cancerColorectal cancerRisk of colorectal cancerCancer prevention optionsFactors associated with useNonsteroidal anti-inflammatory drugsDisease-related factorsChemoprevention uptakeScreening behaviorAspirin chemopreventionRelative risk reductionResearch invitationsPatients' perceptionsLifetime riskAdvocacy websitesASA/NSAID useElectronic surveyFox Chase Cancer CenterPrevention optionsCancer CenterRisk reductionMultivariate modelChemopreventive benefitsParticipantsPrevalence and predictors of aspirin/NSAID use among patients with Lynch syndrome (LS).
Singhal S, Chertok Y, Osorio N, Chavez J, Riggs E, Daly M, Hall M. Prevalence and predictors of aspirin/NSAID use among patients with Lynch syndrome (LS). Journal Of Clinical Oncology 2024, 42: 19-19. DOI: 10.1200/jco.2024.42.3_suppl.19.Peer-Reviewed Original ResearchLynch syndromeAssociated with CPCP useLS patientsPatient advocacy websitesPatient-level factorsPersonal historyColonoscopy surveillanceCP benefitColorectal CAHereditary cancerPatients' perceptionsLifetime riskAdvocacy websitesMarital statusCP usersImpact uptakePrevention benefitsLS participantsPerceptions of CPE-surveyCancer CenterPrevention modalitiesNon-usersPerceived inconvenience